ReviewFrontiers in immunology2022
The Efficacy of Cancer Immunotherapies Is Compromised by
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Global status and trends of gastric cancer and gastric microbiota research: a bibliometric analysis.Frontiers in microbiology · 2024Pooled it
- Advances inOncology letters · 2026Review
- Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions.MedComm · 2026Review
- Review
- Effect ofImmunotherapy · 2025Review
- Article
- Role of Helicobacter pylori virulence factors and alteration of the Tumor Immune Microenvironment: challenges and opportunities for Cancer Immunotherapy.Archives of microbiology · 2024Review
- Helicobacter pylori testing prior to or at gastric cancer diagnosis and survival in a diverse US patient population.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Cross-talk betweenFrontiers in cellular and infection microbiology · 2024Article
- Effects and mechanisms ofFrontiers in immunology · 2024Review
- Immuno-oncology-microbiome axis of gastrointestinal malignancy.World journal of gastrointestinal oncology · 2023Review
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- Establishment of a novel lysosomal signature for the diagnosis of gastric cancer withFrontiers in immunology · 2023Article
- The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy.Frontiers in immunology · 2023Review
- The role of microbiota in the development and treatment of gastric cancer.Frontiers in oncology · 2023Review
- Helicobacter Pylori and Gastric Cancer Progression.Current microbiology · 2022Review
- Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients.BMC cancer · 2022Article
- Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications.Cancers · 2022Review
- Relationships among microbiota, gastric cancer, and immunotherapy.Frontiers in microbiology · 2022Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.